tbuckley/cabot-search huggingface dataset:
SP0054 Experiences from Young Gastroenterologists into Y-ECCO
Authors: P. Hindryckx
Journal: Annals of the Rheumatic Diseases (2016)

The European Crohn9s and Colitis Organisation (ECCO) is an association that aims to improve the care of patients with inflammatory bowel disease through education, research and collaboration. ECCO was founded in 2001 and has been rapidly growing over the past years. The last ECCO congress had almost 7000 attendees. The operational board of ECCO consists of the chairs of the different ECCO committees. Among these ECCO committees is Young-ECCO (Y-ECCO), which was founded in 2007 as a platform for young IBD physicians and scientists that are below 35 years of age or still in training, in order to promote friendship and collaboration between them. Y-ECCO has initiated numerous activities within ECCO (for example, a workshop on career development, literature reviews, a basic science workshop, …) and closely collaborates with the other ECCO committees to fulfill the mission of ECCO. <h3>Disclosure of Interest</h3> None declared
Oligoclonal T Cells Associated with Gvhd Following Allogeneic Stem Cell Transplantation Conditioned with Thymoglobulin and Reduced Intensity Total Body Irradiation.
Authors: Masoud Manjili, Catherine H Roberts, Maciej Kmieciak, Madhu S Gowda, Andrea Ferreira-Gonzalez, Kellie Archer, Shiyu Song, Harold M Chung, John M. McCarty, Amir Toor
Journal: Blood (2009)
Polymorphisms in Antitrombin (SERPINC1) and Tissue Factor Pathway Inhibitor (TFPI) Genes Are Associated with Recurrent Pregnancy Loss
Authors: Elvira Maria Guerra-Shinohara, Juliano Felix Bertinato, Kelma Cordeiro da Silva Giusti, Fernanda Midori Seino, Carolina Tosin Bueno, Mario Henrique Burlacchini de Carvalho, Antônio Gomes Amorim Filho, Marcelo Zugaib, Carlos S Chiattone
Journal: Blood (2011)
AB0480 Cancer Incidence in Systemic Lupus Erythematosus Patients: Table 1
Authors: M. Fernández Matilla, E. Grau Garcia, G. Poveda Marín, C. Feced Olmos, E. Labrador Sánchez, F.M. Ortiz Sanjuan, N. Fernández-Llanio, D. Hervás Marín, V. Fornes Ferrer, K. Arévalo Ruales, R. Negueroles Albuixech, J. Ivorra Cortés, J. Fragio Gil, I. Martínez Cordellat, J. Valero Sanz, I. Chalmeta Verdejo, L. González Puig, C. Alcañiz Escandell, C. Nájera Herranz, J. Castellano Cuesta, J. Román Ivorra
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> In the latest study published by the SEOM (Spanish Society of Medical Oncology) in 2012, the most prevalent types of cancers in Spanish women are breast, colorectal, corpus uteri, lung and ovary. In addition, in Systemic Lupus Erythematosus (SLE) patients a higher incidence of cancer has been described, about 15–20% higher. Today, there is some controversy around the activity on SLE or even drugs employed such as cyclophosphamide could be an extra risk factor for cancer development in these patients. In fact, there are not many studies regarding cancer incidence in SLE. <h3>Objectives</h3> To analyze the cancer incidence in a series of SLE patients, as well as their clinical characteristics. <h3>Methods</h3> Cross-sectional retrospective study of SLE patients according to the SLICC-2012 criteria, coming from the Rheumatology Service of Arnau de Vilanova Hospital and La Fe Hospital. In all patients clinical and disease activity data were collected, using personal interview and medical history. <h3>Results</h3> A total of 140 patients were evaluated; of them, 95% were women with 33.39±13.63 year-old average at the diagnosis time with a 10.05±11.42 year-evolution of SLE. Of them, 6 patients (4.3%) have had some type of cancer, whose clinical characteristics are presented in the table. <h3>Conclusions</h3> The percentage of SLE patients who have developed any type of cancer was 4.3%, which doubles the rate for Spanish general population (2.12%). The types of found cancer are heterogeneous and don9t correspond to the usual pattern described for general population in our country. <h3>Disclosure of Interest</h3> None declared
Proteomic Analysis Reveals That the Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Inhibits Megakaryopoiesis by Preventing Apoptosis
Authors: Michela Di Michele, Karen Peeters, Serena Loyen, Etienne Waelkens, Lutberg Overbergh, Marc Hoylearts, Christel Van Geet, Kathleen Freson
Journal: Blood (2010)
Superior Quality of Life Scores in Patients Over 60 Years of Age in Allogeneic Hematopoietic Cell Transplant.
Authors: Betty K. Hamilton, Housam Haddad, Jane Dabney, Brian J. Bolwell, Lisa Rybicki, Linda McLellan, Larry Foster, Michele Cooper, Shawnda Tench, Matt Kalaycio, Ronald Sobecks, Robert M. Dean, Brian T. Hill, Hien K. Duong, Edward A. Copelan
Journal: Blood (2012)
FRI0485 Comparative Study on Adalimumab vs Infliximab for Treatment of Uveitic Cystoid Macular Edema Due To Behcet's Disease. Multicentre Study of 34 Patients
Authors: E. Beltrán-Catalán, V. Calvo-Rio, R. Blanco-Alonso, C. Fernandez, P. Rodriguez, M. Hernandez, J.M. Herreras, M. Cordero, M. Mesquida, A. Adan, M.V. Hernandez, D. Diaz-Valle, I. Torre, M. Diaz, O. Maiz, S. Insua, F. Francisco, R. Almodovar, O. Ruiz, F. Jimenez, J. Manero, M. Gandia, J.M. Nolla, M.A. Gonzalez-Gay
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> Cystic macular edema (CME) is the most serious complication of uveitis and the most common cause of blindness. Our objective was to compare the efficacy and safety of adalimumab (ADA) vs infliximab (IFX) as the first biological drug in uveitic cystoid macular edema (CME) due to Behçet9s disease (BD) during 1 year follow-up. <h3>Methods</h3> In a multicentre study of 175 patients with BD and uveitis refractory to conventional therapy, 34 patients had CME, defined by (OCT &gt;300μ) at baseline. IFX (3–5 mg/kg 0,2, and 6 weeks and then every 4–8 weeks) was used in 12 cases and ADA (40 mg/2 weeks) in 22 cases. The main objective was the absence of CME. Secondary objectives: improvement in visual acuity (VA) (increased AV &gt;20% in at least one of two eyes), inactive anterior chamber inflammation, vitritis, retinitis and retinal vasculitis. A bivariate analysis was performed to compare the response to biological therapy (ADA and IFX). <h3>Results</h3> We studied 34 patients (63 affected eyes). No statistically significant baseline differences were observed between both groups (IFX vs ADA) sex (men/women 4/6 vs 11/11; p=0.35), mean age (37.3±10.1 vs 41.5±8.3; p=0.2) HLAB51 positive (70% vs 80.9%; p=0.5), duration of uveitis before anti TNF alpha treatment [median (IQR]; 36 [10–82] vs 33 months [15.5 to 83]; p=0.8), VA (0.4 ± 0.33 vs 0.46±0.29; p=0.44); retinal vasculitis (75% vs 77%; p=0.87); retinitis (46% vs 30%; p=0.2); macular thickening (140.9±410.13 vs 409.46±138.55; p=0.98); combined treatment (58.33% vs 59.1%; p=0.96). We found differences in the presence of cells in the anterior chamber (Median [IQR]; 1 [0–1.2] vs 1 [0–3]; p=0.02) and vitritis (median [IQR], 1 [0–2] vs. 3 [0.5 -3]; p=0.002). Regarding the main objective, the improvement of CME is higher in patients treated with ADA during first month of treatment maintained at a year, although the difference is not statistically significant (table). With IFX we observed an improvement during the first month of treatment in vitritis, that became inactive, in the disappearance of the anterior chamber cells, and in retinitis and vasculitis that also became inactive. In no case statistically significant differences are reached. When adjusting for duration of illness, age and sex these differences remain. After a year of treatment all patients with retinitis and vasculitis in its baseline improve (ADA and IFX). <h3>Conclusions</h3> Our study suggests that ADA and IFX don9t show statistically significant differences in treatment of CME due to refractory uveitis in BD after 1 year follow-up. <h3>Disclosure of Interest</h3> None declared
Standard Dose Chemotherapy 3+7 Induces Complete Remission in Patients Over 80 Years Old with Single-Lineage Acute Myeloid Leukemias and Normal Karyotype
Authors: Petr Lemez, Jirina Galikova, Kyra Michalova, Alan MacWhannell, Zuzana Zemanova, Jan Stejskal
Journal: Blood (2008)
Microarray-based analysis and clinical validation identify ubiquitin-conjugating enzyme E2E1 (UBE2E1) as a prognostic factor in acute myeloid leukemia
Authors: Hongmei Luo, Yu Qin, Frederic Reu, Sujuan Ye, Yang Dai, Jingcao Huang, Fangfang Wang, Dan Zhang, Ling Pan, Huanling Zhu, Yu Wu, Ting Niu, Zhijian Xiao, Yuhuan Zheng, Ting Liu
Journal: Journal of Hematology & Oncology (2016)

Background: Previous research suggested that single gene expression might be correlated with acute myeloid leukemia (AML) survival.Therefore, we conducted a systematical analysis for AML prognostic gene expressions. Methods:We performed a microarray-based analysis for correlations between gene expression and adult AML overall survival (OS) using datasets GSE12417 and GSE8970.Positive findings were validated in an independent cohort of 50 newly diagnosed, non-acute promyelocytic leukemia (APL) AML patients by quantitative RT-PCR and survival analysis.Results: Microarray-based analysis suggested that expression of eight genes was each associated with 1-year and 3-year AML OS in both GSE12417 and GSE8970 datasets (p < 0.05).Next, we validated our findings in an independent cohort of AML samples collected in our hospital.We found that ubiquitin-conjugating enzyme E2E1 (UBE2E1) expression was adversely correlated with AML survival (p = 0.04).Multivariable analysis showed that UBE2E1 high patients had a significant shorter OS and shorter progression-free survival after adjusting other known prognostic factors (p = 0.03).At last, we found that UBE2E1 expression was negatively correlated with patients' response to induction chemotherapy (p < 0.05).Conclusions: In summary, we demonstrated that UBE2E1 expression was a novel prognostic factor in adult, non-APL AML patients.
Inappropriate Opioid Dosing and Prescribing for Children
Authors: Terri Voepel-Lewis, Shobha Malviya, Alan R. Tait
Journal: JAMA Pediatrics (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Does Iron Overload Really Matter in Stem Cell Transplantation?
Authors: Philippe Armand, Marie-Michele Sainvil, Haesook T Kim, Joanna Rhodes, Corey Cutler, Vincent T Ho, John Koreth, Edwin P Alyea, Ellis J. Neufeld, Raymond Y Kwong, Robert J. Soiffer, Joseph H. Antin
Journal: Blood (2011)
Clinical Impact of CD8+ Cells in Hodgkin Lymphoma Lymphadenopaties. Contribution of Flow Cytometry
Authors: Sara Alonso, Maria Belen Vidriales, Maria Dolores Caballero, Oscar Blanco, J Galende, Maria Jesús Peñarrubia, Esther Zato, Abelardo Barez, Julio Davila, Juan Carlos Caballero, Alberto Orfao, Marcos González, Ramon Garcia-Sanz
Journal: Blood (2015)
Burnout in surgeons and organisational interventions
Authors: Megumi Hirayama, Senaka Fernando
Journal: Journal of the Royal Society of Medicine (2016)

The high level of burnout in surgeons will continue to grow as continuous healthcare reforms and financial constraints imposed by governments increase personal and professional pressures on surgeons. The many possible causes of burnout in surgeons can be categorised as organisational contributors (e.g. administrative demand and long working hours) and interpersonal contributors (e.g. work–home conflict). Interventions to prevent burnout in surgeons still very much focus on individual approaches, such as stress management. Evidence suggests that organisational interventions initiated by employers in the healthcare sector (e.g. creating opportunities for flexible working hours) have longer lasting and effective outcomes. Indeed, medical councils, such as the General Medical Council in the UK, also have a significant role to play in combating burnout in surgeons by taking radical actions to transform medical education, reflecting the challenges in contemporary healthcare organisations.
Utility of F-18 FDG PET/CT for the Diagnosis and Therapeutic Management of Extranodal Natural Killer (NK)/T-Cell Lymphoma, Nasal Type
Authors: Bing Xu, Rongwei Li, Pengcheng Shi, Huijuan Dong, Xutao Guo, Zhiping Fan, Fen Huang
Journal: Blood (2014)
P-Selectin in Recipients of Allogeneic Bone Marrow Transplantation Regulates Experimental Graft-Versus-Host-Disease.
Authors: Sydney X Lu, Maria Lia Palomba, Il-Kang Na, Theis Terwey, Onder Alpdogan, Jhoanne L Bautista, Marsinay O Smith, David Suh, Christopher King, Uttam Rao, Nury Yim, Robert R. Jenq, Johannes L Zakrzewski, Amanda M. Holland, Olaf Penack, Lindsay Dykstra, Kevin Bampoe, Marcel R.M. van den Brink
Journal: Blood (2009)
Systems Analysis Reveals Regulators of Apoptosis, Cell Cycle, Signal Transduction and Transcription as Novel Direct Targets of the Acute Promyelocytic Leukemia Fusion Protein NuMA-RAR α
Authors: Mahadeo A. Sukhai, Mariam Thomas, Yali Xuan, Patricia P. Reis, Rikki R. Bharadwaj, Suzanne Kamel-Reid
Journal: Blood (2006)
THU0610 The Spondyloarthritis in Sub-Saharan Africa in The Era of Asas Classification Criteria for Axial and Peripheral Spondyloarthritis
Authors: F. Kemta Lekpa, M.S. Doualla, M. Singwe-Ngandeu, H. Namme Luma
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The ASAS classification criteria for axial and peripheral spondyloarthritis have revolutionized the management of patients with suspicion of spondyloarthritis (1,2). These criteria have not been validated in sub-Saharan Africans. Moreover, the application of these new criteria on a population of sub-Saharan Africa with spondyloarthritis has not yet been published. <h3>Objectives</h3> To classify sub-Saharan Africans followed for spondyloarthritis according to the new ASAS classification criteria for axial spondyloarthritis and peripheral spondyloarthritis (1,2). <h3>Methods</h3> We performed a cross-sectional study among 6804 patients seen in the Rheumatology Unit of the Douala General Hospital, a tertiary healthcare centre in Cameroon, between January 2004 and December 2013. All patients followed for spondyloarthritis according to the Amor and/or ESSG criteria were collected to classify them according to the ASAS classification criteria for axial spondyloarthritis and peripheral spondyloarthritis. <h3>Results</h3> Seventy two (27 men and 45 women) patients fulfilled Amor and/or ESSG criteria. The mean age of these patients was 34 ± 13.9 years. The diagnosis was made primarily on the basis of clinical examination and X-rays of the spine and pelvis. No patient achieved a magnetic resonance imaging (MRI). The HLA B27 was negative in all patients tested. Ankylosing spondylitis was the most common spondyloarthritis, followed by reactive arthritis. The distribution of patients according to nosological entities and the predominant topography, axial and/or peripheral are respectively shown in Table 1 and Table 2. Two patients were not classified according to the ASAS criteria. <h3>Conclusions</h3> The ASAS criteria have not changed the epidemiology of spondyloarthritis in Cameroon (prevalence 1.05%), and probably in all the sub-Saharan Africa. The diagnosis is difficult because of the lack of biological markers (HLA B27 negative) and limited access to MRI (available since 2014 in our hospital). Improving the performance of the ASAS criteria for axial and peripheral spondyloarthritis will require numerous other modifications. <h3>References</h3> Rudwaleit M. Ann Rheum Dis. 2009 Jun;68(6):777–83. Rudwaleit M. Ann Rheum Dis. 2011 Jan;70(1):25–31. <h3>Acknowledgement</h3> We gratefully acknowledge Prof. Pascal Claudepierre (Rheumatology, LIC EA4393, Henri Mondor Hospital, Creteil, France) for his critical review and advice on preparing the manuscript. <h3>Disclosure of Interest</h3> None declared
Prevention of Idiopathic Pneumonia Syndrome by Intra-Bone Marrow Injection of Donor Cells
Authors: Yoshiko Yamasuji, Hisakazu Nishimori, Haruko Sugiyama, Koichiro Kobayashi, Sachiyo Okamoto, Eisei Kondo, Nobuharu Fujii, Katsuji Shinagawa, Takuro Kanekura, Mitsune Tanimoto, Yoshinobu Maeda
Journal: Blood (2011)
OP0283 A Randomized Double-Blind Comparative Clinical Trials To Evaluate Efficacy of Vitamin D in Systemic Lupus Erythematosus (SLE) Patients
Authors: W. Lomarat, R. Rattapol Pakchotanon, S. Chaiamnuay, P. Narongroeknawin, P. Asavatanabodee
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> To assess the efficacy and safety of ergocalciferol in combination with standard care in patients with systemic lupus erythematosus (SLE) <h3>Methods</h3> A randomized, double-blinded, placebo-comparative study was conducted in SLE with mild-moderate disease activity. The patients were randomized to receive either high doses of vitamin D (100,000 IU of ergocalciferol weekly for 4 weeks followed by 40,000 IU of ergocalciferol weekly for 20 weeks) or placebo. All patients received 800 unit of cholecalciferol daily for 24 weeks. Concurrent medications could be adjusted as clinically required. Efficacy measures were SLE disease activity index (SLEDAI) score, SLE Flare Index (SFI), inflammatory markers, and dosage of immunosuppressive drugs. The study was approved by the ethic committee and institutional review board <h3>Results</h3> Of the 104 patients enrolled, 88 patients completed the study. Baseline characteristics were similar. At 24 weeks, the mean ± standard difference (SD) of serum 25(OH)D in patients who received high doses of vitamin D was significantly higher than placebo group (41.2 ± 14.4 vs. 27.2 ± 10.1, p&lt;0.001). There was no difference between patients who received high doses of vitamin D and placebo in respect of SLEDAI, SFI, inflammatory markers, and dosage of immunosuppressive drugs. However, at 12 and 24 weeks, the number of patient who can reduce prednisolone dosages in patients who received high doses of vitamin D were significantly greater than that of the placebo (39.6% vs.17.6%, p=0.008) and (43.4% vs. 23.5%, p=0.013). Adverse reactions in both groups were similar. Serum calcium levels did not change within and between groups of treatment. <h3>Conclusions</h3> This study could not demonstrate the efficacy of high dose ergocalciferol in controlling SLE disease activity. However, high dose ergocalciferol could be an adjunctive therapy that safe and has a corticosteroid-sparing effect on patients with SLE <h3>Disclosure of Interest</h3> None declared
Late Consolidation for Patients with Standard Risk AML up to 60 Years: Results of a Prospective Randomized Comparison of High Dose AraC and Autologous PBSCT.
Authors: Arnold Ganser, Jürgen Krauter, Dieter Hoelzer, Oliver Ottmann, Hans Martin, Michael Lübbert, Jürgen Finke, Wolf Heit, Walter Fiedler, Dieter Hossfeld, Lothar Kanz, Günter Schlimok, Hartmut Kirchner, Aruna Raghavachar, Wolfram Brugger, Gerhard Heil
Journal: Blood (2004)
Pediatric Out-of-Hospital Cardiac Arrest
Authors: Sarah E. Haskell, Dianne L. Atkins
Journal: JAMA Pediatrics (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Maintenance Hypomethylating Therapy Post Allogeneic Stem Cell Transplantation Provides Favorable Progression Free Survival in High Risk Acute Myelogenous Leukemia or Non Responsive Myelodysplastic Syndrome
Authors: Connie A. Sizemore, Xu Zhang, Melissa Sanacore, Asad Bashey, Scott R. Solomon, Lawrence E. Morris, H. Kent Holland
Journal: Blood (2012)
Wilms’ Tumor 1 Expression Levels in Bone Marrow after Induction and/or Consolidation Therapy Allow a Better Stratification of Patients and Improves Treatment in Adult AML
Authors: Carolina Martínez-Laperche, Mi Kwon, Ana Carolina Franco, Carmen Chillon, Nerea Castro, Eduardo Anguita, Carlos Rodriguez, Sandra Dolz, Lourdes Hermosín, Elena Buces, Miriam López-Parra, Maria Isabel Prieto, Fernando Ramos-Ortega, J Nicolás Rodriguez, Eva Barragan, Maite Gómez-Casares, Rosa M. Ayala, Joaquín Martínez, Marcos González, José Luis Díez Martín, Ismael Buno
Journal: Blood (2014)